SCHEMBL280094

SCHEMBL280094

Cc1ccc(C(=O)NCC2CCCO2)cn1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.71
MEN1 O00255 1/20 0.71
HPGD P15428 13/20 0.67
SMN1; SMN2 Q16637 8/20 0.67
ALDH1A1 P00352 3/20 0.67
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
LMNA P02545 1/20 0.62
POLB P06746 1/20 0.62
MAPT P10636 1/20 0.62
KDM4E B2RXH2 1/20 0.60
TSHR P16473 2/20 0.59
CYP1A2 P05177 1/20 0.58
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5422109 1.00 KMT2A (0.71) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL5424557 1.00 KMT2A (0.71) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL13210604 0.86 KMT2A (0.72) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL13450229 0.85 KMT2A (0.71) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL279957 0.83 KMT2A (0.86) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL11918653 0.83 KMT2A (0.86) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL5553367 0.81 HPGD (0.71) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1
SCHEMBL5433116 0.80 MMP13 (0.56) KMT2AMEN1POLBKDM4E
SCHEMBL5420230 0.80 GABRA1 (0.60) KDM4E
SCHEMBL6570578 0.79 KMT2A (0.88) KMT2AMEN1HPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885MEN1 605/4885HPGD 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.